Inclusion bodies

CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease

Retrieved on: 
Wednesday, April 29, 2020
Organ systems, Rare diseases, Neurological disorders, Medicine, Lipid storage disorders, Arimoclomol, Piperidines, Inclusion body myositis, Myositis, Niemann, Inclusion bodies, Amyotrophic lateral sclerosis

In addition, in the rest of the world Orphazyme indicated they are finalizing partnering for key countries, including Japan, Canada and Turkey.

Key Points: 
  • In addition, in the rest of the world Orphazyme indicated they are finalizing partnering for key countries, including Japan, Canada and Turkey.
  • CytRx would be eligible to receive future milestone and royalty payments from our arimoclomol agreement.
  • Arimoclomol is in clinical development at Orphazyme for the treatment of Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and amyotrophic lateral sclerosis (ALS).
  • Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM).CytRx Corporation's website is www.cytrx.com .

CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C

Retrieved on: 
Tuesday, July 30, 2019
Neurological disorders, Organ systems, Rare diseases, Medicine, Lipid storage disorders, Inclusion body myositis, Niemann–Pick disease, type C, Niemann–Pick disease, Myositis, Inclusion bodies, Niemann, Amyotrophic lateral sclerosis

As previously announced, Orphazyme intends to file a Marketing Authorization Application (MAA) in Europe in the first half of 2020.

Key Points: 
  • As previously announced, Orphazyme intends to file a Marketing Authorization Application (MAA) in Europe in the first half of 2020.
  • Arimoclomol is in clinical development at Orphazyme for the treatment of Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and amyotrophic lateral sclerosis.
  • Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM).
  • Arimoclomol, the company's lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis.

CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C

Retrieved on: 
Wednesday, June 19, 2019
Medicine, Health, Branches of biology, Lipid storage disorders, Rare diseases, Inclusion body myositis, Niemann–Pick disease, type C, Myositis, Inclusion bodies, Niemann, Sclerosis, NPC

"We are pleased with the progress Orphazyme is making with arimoclomol," said Eric Curtis, CytRx's President and Chief Operating Officer.

Key Points: 
  • "We are pleased with the progress Orphazyme is making with arimoclomol," said Eric Curtis, CytRx's President and Chief Operating Officer.
  • "NPC is a severely debilitating and fatal disease that predominantly affects children and we commend Orphazyme for their commitment to bringing arimoclomol to patients suffering from this devastating disease."
  • Arimoclomol is in clinical development at Orphazyme for the treatment of Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and amyotrophic lateral sclerosis.
  • Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM).